Overactive Bladder Treatment Guidelines

Introduction to Treatment Options

The American Urological Association recommends behavioral therapies as the first-line treatment for overactive bladder, with options including bladder training, delayed voiding, pelvic floor muscle training, fluid management, weight loss, and caffeine reduction 1, 2, 3

Behavioral therapies should be offered to all patients with overactive bladder before medication, including bladder training and delayed voiding, pelvic floor muscle training, fluid management (25% reduction in fluid intake), weight loss for obese patients (8% weight loss can reduce urgency incontinence by 42%), and caffeine reduction 1, 2, 3
Antimuscarinic medications are the second-line treatment for overactive bladder, with options including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium, all showing similar efficacy but different side effect profiles 1, 2
The European Association of Urology recommends oral antimuscarinic options, including darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, and trospium, for patients who fail behavioral therapies 1, 4

All antimuscarinic medications have similar efficacy profiles, with common side effects including dry mouth, constipation, dry eyes and blurred vision, dyspepsia, urinary tract infection, urinary retention, and impaired cognitive function 1, 2
The American Urological Association recommends considering the side effect profile when selecting an antimuscarinic medication, with options including transdermal oxybutynin for patients with dry mouth concerns 1

Antimuscarinic medications are contraindicated in patients with narrow-angle glaucoma, impaired gastric emptying, history of urinary retention, and patients using solid oral forms of potassium chloride 1, 2

Most patients experience significant symptom reduction but not complete relief, with patients with more severe symptoms typically experiencing greater reductions 1, 2

Failure to try behavioral therapies first, overlooking contraindications, not checking post-void residual (PVR) in patients at higher risk of urinary retention, setting unrealistic expectations, not addressing side effects promptly, and not considering drug interactions are common pitfalls to avoid 1, 2

For patients who fail behavioral and medical therapy, referral to a specialist is recommended for consideration of neuromodulation therapy and onabotulinumtoxinA injections 1